Daré Bioscience

Daré Bioscience is a mission-driven biotech dedicated to closing the care gap in the historically underfunded field of women's health. Its strategy centers on developing and commercializing novel, often non-hormonal products through rigorous clinical development, with its first FDA-approved product, DARE to PLAY™ (Sildenafil Cream), now available via telehealth. The company's pipeline is broad, targeting key life stages from contraception to menopause, and is supported by strategic government funding, including a $10 million ARPA-H contract for its HPV program.

A development strategy focused on the repurposing/reformulation of known pharmacological agents for novel female-specific indications, with an emphasis on localized/topical administration and rigorous clinical validation as a key differentiator.

Faces competition from both established pharmaceutical products and direct-to-consumer wellness brands. Differentiates through rigorous clinical science, a pure-play focus on women's health, and a strategy of repurposing drugs for novel, localized applications in this specialty.